

SHEET 1 OF 1

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 4172-3-2	SERIAL NO. 10/076,071
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANT BAR-OR et al.	
		FILING DATE February 13, 2002	GROUP ART 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.
<i>NP</i>	AA	5,538,945	7/23/96	Pallenberg et al.	514	6	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

<i>NP</i>	AB	Battegay, E.J., "Angiogenesis: Mechanistic Insights, Neovascular Diseases, and Therapeutic Prospects," <i>Journal of Molecular Medicine</i> , 1995, Vol. 73, pp. 333-346.

RECEIVED

TECH CENTER 1600/2900

RECEIVED

FEB 21 2003

TECH CENTER 1600/2900

EXAMINER <i>NP</i>	DATE CONSIDERED <i>9/14/04</i>
-----------------------	-----------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 4172-3-2	SERIAL NO. 10/076,071
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANT BAR-OR et al.	
		FILING DATE February 13, 2002	GROUP ART 1614

RE JC88
JUN 18 2002
PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.
<i>DP</i>	1	6,084,093	7/4/00	Riley et al.	540	465	
<i>DP</i>	2	6,083,758	7/4/00	Imperiali et al.	436	73	
<i>DP</i>	3	6,022,879	2/8/00	Crow et al.	514	319	
<i>DP</i>	4	6,017,888	1/25/00	Pallenberg et al.	514	19	
<i>DP</i>	5	6,004,953	12/21/99	Volpin et al.	514	185	
<i>DP</i>	6	5,994,339	11/30/99	Crapo et al.	514	185	
<i>DP</i>	7	5,922,761	7/13/99	Lal	514	476	
<i>DP</i>	8	5,906,996	5/25/99	Murphy	514	674	
<i>DP</i>	9	5,888,522	3/30/99	Pickart	424	401	
<i>DP</i>	10	5,874,573	2/23/99	Winchell et al.	540	465	
<i>DP</i>	11	5,858,993	1/12/99	Pickart	514	60	
<i>DP</i>	12	5,807,535	9/15/98	Smith et al.	424	1.65	
<i>DP</i>	13	5,786,335	7/28/98	Cody et al.	514	17	
<i>DP</i>	14	5,785,948	7/28/98	Itaya et al.	424	1.69	
<i>DP</i>	15	5,780,594	7/14/98	Carter	530	363	
<i>DP</i>	16	5,776,892	7/7/98	Counts et al.	514	11	
<i>DP</i>	17	5,770,178	6/23/98	Itaya et al.	424	1.69	
<i>DP</i>	18	5,739,395	4/14/98	Bergeron, Jr.	562	565	
<i>DP</i>	19	5,710,172	1/20/98	Kukreja et al.	514	400	
<i>DP</i>	20	5,683,907	11/4/97	Johnson	436	518	
<i>DP</i>	21	5,670,645	9/23/97	Johnson	546	141	
<i>DP</i>	22	5,670,627	9/23/97	Johnson	530	388.9	
<i>DP</i>	23	5,663,301	9/2/97	Johnson	530	363	
<i>DP</i>	24	5,654,160	8/5/97	Johnson	435	7.9	
<i>DP</i>	25	5,650,134	7/22/97	Albert et al.	424	1.69	
<i>DP</i>	26	5,639,624	6/17/97	Wagner et al.	435	7.92	

EXAMINER

DATE CONSIDERED

9/14/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 4172-3-2	SERIAL NO. 10/076,071
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANT BAR-OR et al.	
		FILING DATE February 13, 2002	GROUP ART 1614


RE JC68
JUN 18 2002
PATENT & TRADEMARK OFFICE

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.
<i>JP</i>	27	5,637,578	6/10/97	Riley et al.	514	186
<i>JP</i>	28	5,637,311	6/10/97	Pallenberg	424	434
<i>JP</i>	29	5,631,172	5/20/97	Johnson	436	543
<i>JP</i>	30	5,628,982	5/13/97	Lauffer et al.	424	9.363
<i>JP</i>	31	5,624,900	4/29/97	Suda et al.	514	13
<i>JP</i>	32	5,591,711	1/7/97	Koyama et al.	514	6
<i>JP</i>	33	5,585,466	12/17/96	Carter	530	363
<i>JP</i>	34	5,554,375	9/10/96	Pickart	424	401
<i>JP</i>	35	5,550,183	8/27/96	Pickart	514	6
<i>JP</i>	36	5,538,945	7/23/96	Pallenberg et al.	514	6
<i>JP</i>	37	5,527,522	6/18/96	Lauffer et al.	424	9.362
<i>JP</i>	38	5,503,987	4/2/96	Wagner et al.	435	7.94
<i>JP</i>	39	5,476,939	12/19/95	Johnson	546	141
<i>JP</i>	40	5,470,876	11/28/95	Proctor	514	492
<i>JP</i>	41	5,455,229	10/3/95	Hahn et al.	514	18
<i>JP</i>	42	5,422,096	6/6/95	Lauffer et al.	424	9.363
<i>JP</i>	43	5,382,431	1/17/95	Pickart	424	401
<i>JP</i>	44	5,380,747	1/10/95	Medford et al.	514	423
<i>JP</i>	45	5,348,943	9/20/94	Pickart	514	18
<i>JP</i>	46	5,290,519	3/1/94	Bar-Or et al.	522	61
<i>JP</i>	47	5,252,559	10/12/93	Kronholm et al.	514	18
<i>JP</i>	48	5,227,307	7/13/93	Bar-Or et al.	436	63
<i>JP</i>	49	5,214,032	5/25/93	Pickart	514	16
<i>JP</i>	50	5,177,061	1/5/93	Pickart	514	18
<i>JP</i>	51	5,164,367	11/17/92	Pickart	514	6
<i>JP</i>	52	5,145,838	9/8/92	Pickart	514	18
<i>JP</i>	53	5,135,913	8/4/92	Pickart	514	16

EXAMINER	DATE CONSIDERED
<i>ASB</i>	9/14/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 4172-3-2	SERIAL NO. 10/076,071
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANT BAR-OR et al.	
		FILING DATE February 13, 2002	GROUP ART 1614



*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.
P	5,120,831	6/9/92	Pickart	530	331	
P	5,118,665	6/2/92	Pickart	514	6	
P	5,104,865	4/14/92	Hider et al.	514	188	
P	5,101,041	3/31/92	Troutner et al.	548	518	
P	5,087,696	2/11/92	Parker et al.	540	465	
P	5,059,588	10/22/91	Pickart	514	12	
P	5,023,237	6/11/91	Pickart	514	18	
P	4,912,118	3/27/90	Hider et al.	514	332	
P	4,877,770	10/31/89	Pickart	514	18	
P	4,810,693	3/7/89	Pickart	514	18	
P	4,767,753	8/30/88	Pickart	514	18	
P	4,760,051	7/26/88	Pickart	514	6	
P	4,746,649	5/24/88	Raddatz et al.	514	18	
P	4,684,624	8/4/87	Hosobuchi et al.	514	15	
P	4,665,054	5/12/87	Pickart	514	18	
P	4,591,648	5/27/86	Jones et al.	548	344	
P	4,461,724	7/24/84	Konishi	260	112.5	
P	4,025,499	5/24/77	Thomas	260	112.5	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
						YES	NO
72	WO 00/20840	4/2000	PCT				
73	WO 00/20454	4/2000	PCT				
74	WO 99/45907	9/1999	PCT				
75	WO 99/39706	8/1999	PCT				

EXAMINER

DATE CONSIDERED

9/14/94

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 4172-3-2	SERIAL NO. 10/076,071
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANT BAR-OR et al.	
		FILING DATE February 13, 2002	GROUP ART 1614

JC68
JUN 18 2002
PATENT & TRADEMARK OFFICE

76	WO 98/54138	12/1998	PCT		
77	EP 0613560 B1	10/1998	EPO		
78	WO 98/40071	9/1998	PCT		
79	WO 97/49409	12/1997	PCT		
80	WO 97/44313	11/1997	PCT		
81	719790	12/1995	EPO		
82	WO 94/26295	11/1994	PCT		
83	WO 93/23425	11/1993	PCT		
84	WO 93/10459	5/1993	PCT		
85	WO 91/17760	11/1991	PCT		
86	327263	1/1989	EPO		
87	JP 62116565	5/1987	Japan		
88	WO 00/21941	4/20/00	PCT		

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

89	"Angiogenesis Inhibitors," found at http://www.cancerprotocol.com/angiogenesis_inhibitors.html , January 28, 2002, 1 page
90	"Metal Heads," from New Scientist, 26/8/00, found at http://purdeyenvironment.com/Full%20New%20scientist0001.htm , 6 pages
91	"Metal-Binding Groups of Proteins: A. Evidence for Specific Donor Atoms," Chapter IV, pp. 61-99
92	"The Role of Copper in the Angiogenesis Process," found at http://www.cancerprotocol.com/role_of_copper.html , January 28, 2002, 2 pages
93	"Toxicity and Physicochemical Properties of Metal: Coordination and Chelation," Ch. 4, pp. 115-122
94	Adman, <i>Advances in Protein Chemistry</i> , 42:145-197 (1991)
95	Afans'ev, Superoxide Ion: Chemistry and Biological Implications, Vol. I, pp. 26, 51, 147, 168-196, 248-266 (CRC Press, Boca Raton, FL) (1989)
96	Altken, <i>Mol. Biotech.</i> , 12:241-253 (1999)
97	Ames et al., <i>Proc. Natl. Acad. Sci. USA</i> , 90:7915-7922 (1993)
98	Atanasiu et al., <i>Mol. Cell. Biochem.</i> , 189:127-135 (1998)
99	Atwood et al., <i>J. Biol. Chem.</i> , 273(21):12817-12826 (1998)

EXAMINER	DATE CONSIDERED
	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 4172-3-2	SERIAL NO. 10/076,071
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANT BAR-OR et al.	
		FILING DATE February 13, 2002	GROUP ART 1614

JUN 18 2002
PATENT & TRADEMARK OFFICE

100	Aust, <i>Bibl. Nutr. Dieta.</i> Basel, Karger, No. 43, pp. 266-277 (1989)
101	Bal et al., <i>Chem. Res. Toxicol.</i> , 10(8):906-914 (1997)
102	Bal et al., <i>Chem. Res. Toxicol.</i> , 10:915-921 (1997)
103	Bar-Or et al., <i>Biochem. Biophys. Res. Commun.</i> , 284:856-862 (2001)
104	Bar-Or et al., <i>Biochem. Biophys. Res. Commun.</i> , 282:356-360 (2001)
105	Bar-Or et al., <i>Free Rad. Biol. Med.</i> , 32(2):197-199 (2002)
106	Bar-Or et al., abstr. P416 in American Peptide Society "Abstract Book" from 17th American Peptide Symposium, San Diego, California, June 2001
107	Bar-Or et al., <i>Biochem. Biophys. Res. Commun.</i> , 290:1388-1392 (2002)
108	Bar-Or et al., text of poster presented at 17th American Peptide Symposium, San Diego, California, June 2001, found at http://www.5z.com/aps/219/02
109	Beaulieu et al., <i>J. Cerebral Blood Flow and Metabolism</i> , 18:1022-1031 (1998)
110	Belayev et al., <i>J. Neurotrauma</i> , 16(6):445-453 (1999)
111	Boggs, "Copper chelation suppresses experimental liver tumor growth," found at http://www.buntsmancancer.org/content/reuters/2001/12/21/200112221scle001.html , January 28, 2002
112	Bossu et al., <i>Inorganic Chemistry</i> , 17(4):1034-1042 (1978)
113	Bourdon et al., <i>FASEB J.</i> , 13:233-244 (1999)
114	Buranaprapuk et al., <i>Biochim Biophys Acta</i> , 1387:309-316 (1998)
115	Calabrese et al., <i>Biochem. J.</i> , 238:291-295 (1986)
116	Canfers et al., <i>FEBS</i> , 325(1,2):39-48 (1993)
117	Chakrabarti, <i>Protein Engineering</i> , 4(1):57-63 (1990)
118	Chan et al., <i>Eur. J. Biochem.</i> , 227:524-528 (1995)
119	Cotelle et al., <i>J. Inorganic Biochemistry</i> , 46:7-15 (1992)
120	Das et al., <i>Methods in Enzymology</i> , 233:601-611 (1994)
121	Davies, <i>J. Biol. Chem.</i> , 262(20):9902-9907 (1987)
122	Davies, <i>J. Biol. Chem.</i> , 262(20):9895-9901 (1987)
123	Davies, <i>J. Biol. Chem.</i> , 262(20):9914-9920 (1987)
124	Davies, <i>J. Biol. Chem.</i> , 262(20):9908-9913 (1987)
125	Duchette et al., "Copper Reduction Therapy as an Antiangiogenic Treatment for Lymphoma and other Cancers," found at http://www.coldcure.com/html/anti-ang.htm , 3/5/01, 23 pages

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 4172-3-2	SERIAL NO. 10/076,071
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANT BAR-OR et al.	
		FILING DATE February 13, 2002	GROUP ART 1614

PATENT & TRADEMARK OFFICE
JUN 18 2002
F-1C68

126	Dunphy et al., <i>Am. J. Physiol.</i> , 276:H1591-H1598 (1999)
127	Farkas et al., <i>J. Chem. Soc. Dalton Trans.</i> , pp. 611-614 (1984)
128	Florence, <i>Australian and New Zealand J. Ophthalmol.</i> , 23(1):3-7 (1995)
129	Fu et al., <i>Biochem. J.</i> , 333:519-525 (1998)
130	Gutteridge et al., <i>Biochim. Biophys. Acta</i> , 759:38-41 (1983)
131	Halliwell et al., <i>Arch. Biochem. Biophys.</i> , 246(2):501-514 (1986)
132	Halliwell et al., "Free Radicals in Biology and Medicine" pp. 1-21 (2nd ed. Clarendon Press - Oxford 1989)
133	Halliwell et al., <i>Arch. Biochem. Biophys.</i> , 280(1):1-8 (1990)
134	Harford et al., <i>Acc. Chem. Res.</i> , 30:123-130 (1997)
135	He et al., <i>Biochemistry</i> , 38:9704-9711 (1999)
136	Hirose et al., <i>Biochim. Biophys. Acta</i> , 1296:103-111 (1996)
137	Hisatomi et al., <i>Transplantation</i> , 52(4):754-755 (1991)
138	Huh et al., <i>Brain Res.</i> , 804:105-113 (1998)
139	Karck et al., <i>J. Heart Lung Transplant</i> , 11:979-85 (1992)
140	Keller et al., <i>Chem. Res. Toxicol.</i> , 6:430-433 (1993)
141	Kerr et al., <i>Heart Lung</i> , 25:200-9 (1996)
142	Khan et al., <i>Biochem. Pharmacol.</i> , 43(9):1963-1967 (1992)
143	Kimoto et al., <i>Cancer Res.</i> , 43(2):824-828 (1983) Abstr. in PubMed- PMID: 6293704
144	Knight, <i>Ann. Clin. Lab. Sci.</i> , 25(2):111-121 (1995)
145	Koch et al., <i>Chemistry & Biology</i> , 4:549-560 (1997)
146	Kowalik-Jankowska et al., "Copper(II) Complexes with Oligopeptides Containing Serine, Methionine or Phenylalanine Residues" pp. 1184-1197 (9/24/1992)
147	Kowalik-Jankowska et al., <i>J. Inorg. Biochem.</i> , 66:193-196 (1997)
148	Kruck et al., <i>Can. J. Chem.</i> , 54:1300-1308 (1976)
149	Lappin et al., <i>Inorganic Chemistry</i> , 17(6):1630-1634 (1978)
150	Lau et al., <i>Biochem J.</i> , 257(3) 745-750 (1989) Abstr. in PubMed- PMID: 2467660
151	Laussac et al., <i>Biochemistry</i> , 23:2832-2838 (1984)
152	Leeuwenburgh et al., <i>Am J. Physiol.</i> , 274:R453-R461 (1998)
153	Legrand et al., <i>Biochimie</i> , 70:1185-1195 (1988)
154	Little et al., <i>Neurosurgery</i> , 9(5):552-558 (1981)
155	Loban et al., <i>Clinical Science</i> , 93:445-451 (1997)

EXAMINER	DATE CONSIDERED
----------	-----------------

[Signature] 9/18/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 4172-3-2	SERIAL NO. 10/076,071
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANT BAR-OR et al.	
		FILING DATE February 13, 2002	GROUP ART 1614

JUN 18 2002
PATENT & TRADEMARK OFFICE

156	Machonkin et al., <i>Biochemistry</i> , 37:9570-9578 (1998)
157	Malins et al., <i>Proc. Natl. Acad. Sci USA</i> , 93:2557-2565 (1996)
158	Malmström et al., <i>Curr Op. Chem. Biol.</i> , 2:286-292 (1998)
159	Manso, <i>Rev. Port. Cardiol.</i> , 11(11):997-999 (1992)
160	Maret et al., <i>Methods in Enzymology</i> , 226:52-71 (1993)
161	Marx et al., <i>Biochem. J.</i> , 236:397-400 (1985)
162	Masuoka et al., <i>J. Biol. Chem.</i> , 268(29):21533-21537 (1993)
163	McGuirl et al., <i>Curr. Op. Chem. Biol.</i> , 3:138-144 (1999)
164	Miller et al., <i>Arch. Biochem. Biophys.</i> , 295(2):240-246 (1992)
165	Mlynarz et al., "α-Hydroxymethylserine (HMS) Makes HMS-HMS-His the Most Efficient Tripeptide Ligand for Cu ²⁺ Ions" (1998) Speciation 98:Abstract
166	Musci et al., <i>Arch. Biochem. Biophys.</i> , 306(1):111-118 (1993)
167	Odeh, <i>N Eng. J. Med.</i> , 324(20):1417-1422 (1991)
168	Praticò et al., <i>J. Clin. Invest.</i> , 100(8):2028-2034 (1997)
169	Predki et al., <i>Biochem. J.</i> , 287:211-215 (1992)
170	Quinlan et al., <i>J. Pharm. Sci.</i> , 81(7):611-614 (1992)
171	Rao et al., <i>Ann. Thorac. Surg.</i> , 52:908-12 (1991)
172	Regan, <i>Annu. Rev. Biophys. Biomol. Struct.</i> , 22:257-81 (1993)
173	Regan, <i>TIBS</i> 20, pp. 280-285 (1995)
174	Remmers et al., <i>Brain Research</i> , 827:237-242 (1999)
175	Rosenthal et al., <i>Free Radical Biology & Medicine</i> , 12:29-33 (1992)
176	Röth, <i>Acta Chirurgica Hungarica</i> , 36(1-4):302-305 (1997)
177	Rupp et al., <i>Biochim. Biophys. Acta</i> , 446:151-165 (1976)
178	Russell et al., <i>Free Radical Biology & Medicine</i> , 25(2):153-159 (1998)
179	Rylkov et al., <i>Eur. J. Biochem.</i> , 197:185-189 (1991)
180	Sadler et al., <i>Eur. J. Biochem.</i> , 220:193-200 (1994)
181	Salvemini et al., <i>Science</i> , 286:304-306 (1999)
182	Si et al., <i>GLIA</i> , 21:413-418 (1997)
183	Smith et al., <i>J. Histochem. Cytochem.</i> , 46:731-735 (1998)
184	Spencer et al., <i>J. Cardiovasc. Pharmacol.</i> , 32(3):343-348 (1998)
185	Stohs, <i>J. Basic & Clin. Physiol. Pharmacol.</i> , 6(3-4):205-229 (1995)

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 4172-3-2	SERIAL NO. 10/076,071
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANT BAR-OR et al.	
		FILING DATE February 13, 2002	GROUP ART 1614

P E JC68
JUN 18 2002
PATENT & TRADEMARK OFFICE

186	Sutherland et al., abstr. P078 in Abstracts of Communications to be presented at the 10th International Congress on Cardiovascular Pharmacotherapy, Kyoto Japan, March 2001
187	Sutherland et al., <i>J. Cardio. Pharmacol.</i> , 39:722-728 (200-2)
188	Süzer et al., <i>Pharmacol. Res.</i> , 37(2):97-101 (1998)
189	Ueda et al., <i>Chem. Pharm. Bull.</i> , 43(2):359-361 (1995)
190	Ueda et al., <i>Free Radical Biology & Medicine</i> , 18(5):929-933 (1995)
191	Ueda et al., <i>J. Inorgan. Biochem.</i> , 55:123-130 (1994)
192	Whittal et al., <i>Protein Science</i> , 9:332-343 (2000)
193	Wolff et al., <i>TIBS</i> 11, pp. 27-31 (1986)
194	Wysocki et al., <i>Coronary Artery Disease</i> , 4:845-847 (1993)
195	Yamada et al., <i>Biochem. Mol. Biol. Intl</i> , 46(4):733-738 (1998)
V	Yoon et al., <i>J. Surg Res</i> , 46:163-165 (1989)

EXAMINER	DATE CONSIDERED
----------	-----------------

[Handwritten signature]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

9/14/04



SHEET 1 OF 1

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 4172-3-2	SERIAL NO. 10/076,071
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANT BAR-OR et al.	
		FILING DATE February 13, 2002	GROUP ART 1653


U.S. PATENT DOCUMENTS


*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.
AP	AA	6,001,965	12/14/1999	Livant	530	330	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
AP	AB	WO 02/064621	8/22/2002	PCT				
AP	AC	WO 00/13712	3/16/2000	PCT				

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

EXAMINER 	DATE CONSIDERED <u>9/14/04</u>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



SHEET 1 OF 2

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 4172-3-2	SERIAL NO. 10/076,071
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANT BAR-OR et al.	
		FILING DATE February 13, 2002	GROUP ART 1653

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.
AD	6,610,821	8/26/2003	Blaschuk et al.	530	317	
AD	2003/0130185	7/10/2003	Bar-Or et al.	514	12	6/27/2002
AD	6,583,182	6/24/2003	Winchell et al.	514	648	
AD	6,264,966	7/24/2001	Winchell et al.	424	401	
AD	09/678,202	—	Bar-Or et al.	—	—	9/29/2000
AD	6,008,205	12/28/1999	Serhan et al.	514	102	
AD	5,932,548	8/3/1999	Deghenghi	514	15	
AD	5,919,900	7/6/1999	Moyle et al.	530	350	
AD	5,529,907	6/25/1996	Nierman et al.	435	29	
AD	5,270,447	12/14/1993	Liotta et al.	530	326	
AD	4,975,423	12/4/1990	Gaffar	514	108	
AD	4,816,449	3/28/1989	Hahn	514	17	
AD	4,628,045	12/9/1986	Hahn	514	17	
AD	4,323,558	4/6/1982	Nelson	424	164	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
						YES	NO
AD	WO 02/43722	6/6/2002	PCT	A61K	31/132		
AD	WO 00/23469	4/27/2000	PCT	C07K	14/47		
AD	WO 94/14836	7/7/1994	PCT	C07K	1/02		
AD	WO 94/09808	5/11/1994	PCT	A61K	37/02		

EXAMINER	DATE CONSIDERED
<i>Am</i>	<i>9/16/04</i>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

O P E
JUL 30 2004
P A T E N T & T R A D E M A R K O F F I C E
S E R I E S
F O R M P T O - 1 4 4 9

SHEET 2 OF 2

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 4172-3-2	SERIAL NO. 10/076,071
	APPLICANT BAR-OR et al.	
	FILING DATE February 13, 2002	GROUP ART 1653

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

19	Ben-Hamida et al.; "Histamine, Xanthine Oxidase Generated Oxygen-Derived Free Radicals and Helicobacter Pylori in Gastroesophageal Reflux Disease"; <i>Inflammation Research</i> ; 1998; 47:193-199
20	Cameron et al.; "Neurovascular Dysfunction in Diabetic Rats. Potential Contribution of Autoxidation and Free Radicals Examined Using Transition Metal Chelating Agents"; <i>J Clin Invest</i> ; August 1995; 96(2):1159-63; 1 p. Abstract from NCBI PubMed; PMID: 7635953
21	Danielsson et al.; "Nonopsonic Activation of Neutrophils by Helicobacter Pylori is Inhibited by Rebamipide"; <i>Digestive Diseases and Sciences</i> ; September 1998 Supplement; 43(9):167S-173S
22	Iinuma et al.; "Role of Active Oxygen Species and Lipid Peroxidation in Mepirizole-Induced Duodenal Ulcers in Rats"; <i>Digestive Diseases and Sciences</i> ; August 1998; 43(8):1657-1664
23	Love et al.; "Nerve Function and Regeneration in Diabetic and Galactosaeemic Rats: Antioxidant and Metal Chelator Effects"; <i>Eur J Pharmacol</i> ; October 24, 1996; 314(1-2):33-9; 1 p. Abstract from NCBI PubMed; PMID: 8957216
24	Yoshii et al.; "The Copper-Chelating Agent, Trientine, Suppresses Tumor Development and Angiogenesis in the Murine Hepatocellular Carcinoma Cells"; <i>Int J Cancer</i> ; December 15, 2001; 94(6):768-73; 1 p. Abstract from NCBI PubMed; PMID: 11745476

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	